vsv-hifnbeta-nis
Biologicalexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 2, 2013 (NCT01872819)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vsv-hifnbeta-nis
- vsv-ifnbeta-nis
- vsv-ifnβ-nis
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03120624 | Phase 1 | Jun 15, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02923466 | Phase 1 | Apr 17, 2017 | Vyriad, Inc. |
| NCT03017820 | Phase 1 | Apr 4, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01872819 | N/A | Aug 2, 2013 | National Cancer Institute (NCI), University of Washington |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2013 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 1 | 2017 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Vyriad, Inc. | For profit | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1